Literature DB >> 12083507

Heterogeneous detection of A-antigen on von Willebrand factor derived from platelets, endothelial cells and plasma.

Simon A Brown1, Peter W Collins, Derrick J Bowen.   

Abstract

The exact function of the carbohydrate component of von Willebrand factor (VWF) is unknown. ABO blood group antigens are present as integral structures on the oligosaccharide side chains and it has long been recognised that ABO blood group is a determinant of VWF levels. The mechanism for this is not known. Using a monoclonal antibody against the A-antigen, we investigated the presence of this antigen on VWF from plasma, platelets, human umbilical vein endothelial cells (HUVEC) and saphenous vein endothelial cells. Initial studies on plasma VWF revealed that 23.5% of samples appeared to be negative for the A-antigen. This was shown to correlate with the A2 subtype of the A-antigen (p < 0.01). Analysis of intracellular VWF from saphenous vein endothelial cells revealed low levels of A-antigen to be present in comparison to the corresponding plasma VWF. In contrast, VWF from platelets and HUVEC gave no detectable A-antigen. However, within 1 h of administration of DDAVP to type 1 VWD patients, there was a > 2-fold increase in the A-antigen/VWF: Ag ratio for VWF in the plasma. In vitro experiments with serum N-acetlygalactosaminyltransferase failed to demonstrate any addition of A-antigen to platelet or HUVEC VWF. These data are consistent with heterogeneity in the content of A-antigen on VWF from different physiological compartments. Also, they are consistent with either a change in the A-antigen content of VWF after release from the intracellular compartment or a difference in the intracellular addition of A-antigen to VWF by endo thelium from different vascular beds.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12083507

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis.

Authors:  S Kanaji; S A Fahs; Q Shi; S L Haberichter; R R Montgomery
Journal:  J Thromb Haemost       Date:  2012-08       Impact factor: 5.824

2.  Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms.

Authors:  S Albánez; K Ogiwara; A Michels; W Hopman; J Grabell; P James; D Lillicrap
Journal:  J Thromb Haemost       Date:  2016-04-27       Impact factor: 5.824

3.  Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report.

Authors:  E Berntorp; B Fuchs; M Makris; R Montgomery; V Flood; J S O'Donnell; A B Federici; D Lillicrap; P James; U Budde; M Morfini; P Petrini; S Austin; C Kannicht; V Jiménez-Yuste; C Lee
Journal:  Haemophilia       Date:  2013-03       Impact factor: 4.287

4.  Aberrant expression of histo-blood group A type 3 antigens in vascular endothelial cells in inflammatory sites.

Authors:  Mizuho Nosaka; Yuko Ishida; Aki Tanaka; Takahito Hayashi; Tomoko Miyashita; Chikako Kaminaka; Wolfgang Eisenmenger; Fukumi Furukawa; Akihiko Kimura
Journal:  J Histochem Cytochem       Date:  2007-11-12       Impact factor: 2.479

5.  Effects of plasma glycosyltransferase on the ABO(H) blood group antigens of human von Willebrand factor.

Authors:  Taiki Kano; Kazunao Kondo; Jiharu Hamako; Fumio Matsushita; Kazuya Sakai; Taei Matsui
Journal:  Int J Hematol       Date:  2018-04-04       Impact factor: 2.490

6.  Diagnostic Value of Measuring Platelet Von Willebrand Factor in Von Willebrand Disease.

Authors:  Alessandra Casonato; Maria Grazia Cattini; Viviana Daidone; Elena Pontara; Antonella Bertomoro; Paolo Prandoni
Journal:  PLoS One       Date:  2016-08-17       Impact factor: 3.240

Review 7.  The relationship between ABO blood group, von Willebrand factor, and primary hemostasis.

Authors:  Soracha E Ward; Jamie M O'Sullivan; James S O'Donnell
Journal:  Blood       Date:  2020-12-17       Impact factor: 22.113

8.  Sialylation on O-linked glycans protects von Willebrand factor from macrophage galactose lectin-mediated clearance.

Authors:  Soracha E Ward; Jamie M O'Sullivan; Alan B Moran; Daniel I R Spencer; Richard A Gardner; Jyotika Sharma; Judicael Fazavana; Marco Monopoli; Thomas A J McKinnon; Alain Chion; Sandra Haberichter; James S O'Donnell
Journal:  Haematologica       Date:  2022-03-01       Impact factor: 9.941

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.